Ondine Biomedical, Inc. (OBI) AI Stock Analysis

• Market Cap: £50.54M
• Dividend Yield: N/A
• Average Volume (3M): 160.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: 63.25%
• EPS Growth: 8.94%
• Country: UK
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 518,366,940
• 10 Day Avg. Volume: 119,918
• 30 Day Avg. Volume: 160,072
• PEG Ratio: 0.53
• Price to Book (P/B): 6.29
• Price to Sales (P/S): 21.10
• P/FCF Ratio: -2.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -4.53
• Revenue Forecast (FY): £370.23M

• Rating: 37 Underperform
• Price Target: 9.50p ▼(-2.56% Downside)

Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company's strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing demand for OBI's products, suggesting successful market penetration and potential for future expansion.

Low Leverage

Minimal leverage provides financial flexibility and reduces risk, allowing OBI to invest in growth opportunities without significant debt burden.

Innovative Product Offering

The Steriwave system's versatility and innovation in infection control enhance OBI's competitive position in the healthcare sector, supporting long-term growth.

Negative Factors

Profitability Challenges

Ongoing profitability issues indicate operational inefficiencies, which could hinder OBI's ability to sustain growth and invest in new initiatives.

Negative Cash Flow

Negative cash flow raises concerns about OBI's ability to fund operations and growth internally, potentially leading to reliance on external financing.

Operational Inefficiencies

Inefficiencies in operations can limit OBI's ability to capitalize on revenue growth, affecting long-term profitability and market competitiveness.

Ondine Biomedical, Inc. Business Overview & Revenue Model

Company Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Ondine Biomedical generates revenue through the sale of its medical devices and systems, particularly the Steriwave system, to hospitals, clinics, and healthcare providers. The company may also engage in partnerships with healthcare organizations and distributors to expand its market reach and facilitate product adoption. Additionally, OBI could explore revenue streams through licensing agreements or collaborations with research institutions, enabling further development of its technologies while securing additional funding and resources.

Ondine Biomedical, Inc. Financial Statement Overview

Summary

Ondine Biomedical, Inc. demonstrates strong revenue growth, but faces significant challenges with profitability and cash flow. The low leverage is a positive aspect, but operational inefficiencies and poor cash generation hinder sustainable growth.

Income Statement

Ondine Biomedical, Inc. shows significant revenue growth of 70.94% in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins, which reflect ongoing operational challenges. The gross profit margin is relatively healthy at 64.47%, but the negative net income suggests high costs or inefficiencies.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.024, indicating minimal leverage and a conservative capital structure. However, the return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is not explicitly calculated, but the available data suggests a moderate level of equity relative to assets.

Cash Flow

Ondine Biomedical, Inc. has a negative operating cash flow, which is a concern for sustainability. The free cash flow to net income ratio is close to 1, indicating that free cash flow is aligned with net income, albeit both are negative. The company needs to improve its cash generation to support operations and growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.05M	1.20M	638.00K	2.57M	1.79M
Gross Profit	1.32M	703.00K	287.00K	1.25M	649.00K
EBITDA	-18.49M	-13.79M	-18.85M	-48.36M	-14.56M
Net Income	-19.10M	-14.41M	-19.37M	-50.09M	-16.27M
Balance Sheet
Total Assets	12.82M	5.73M	16.57M	34.14M	2.63M
Cash, Cash Equivalents and Short-Term Investments	9.77M	2.98M	13.13M	30.36M	626.00K
Total Debt	168.00K	541.00K	896.00K	739.00K	31.46M
Total Liabilities	5.95M	3.65M	4.92M	4.48M	36.46M
Stockholders Equity	6.88M	2.08M	11.64M	29.66M	-33.81M
Cash Flow
Free Cash Flow	-15.50M	-13.83M	-16.66M	-12.62M	-6.43M
Operating Cash Flow	-15.49M	-13.65M	-16.34M	-12.54M	-6.33M
Investing Cash Flow	-10.00K	-177.00K	-311.00K	-77.00K	2.90M
Financing Cash Flow	21.74M	3.79M	-275.00K	41.90M	3.83M

Ondine Biomedical, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBI, the sentiment is Negative. The current price of 9.75 is below the 20-day moving average (MA) of 10.92, below the 50-day MA of 11.93, and below the 200-day MA of 12.06, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 12.47 is Positive, neither overbought nor oversold. The STOCH value of 13.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBI.

Ondine Biomedical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRX	49 Neutral	£5.16M	-4.90	-5.41%	―	-20.31%	-19.35%
SAR	47 Neutral	£18.64M	-5.19	-202.14%	―	―	23.76%
SBTX	40 Underperform	£35.26M	-41.29	-11.24%	―	283.74%	78.57%
OBI	37 Underperform	£50.54M	-2.46	―	―	63.25%	8.94%

Ondine Biomedical, Inc. Corporate Events

Ondine Biomedical’s Steriwave Shows Promising Results in ICU Pathogen Reduction

Ondine Biomedical Inc. announced significant results from its Steriwave ICU Pilot Study at Royal Columbian Hospital, demonstrating a substantial reduction in harmful pathogens among critically ill ICU patients. The study highlights Steriwave’s potential as a non-antibiotic infection-prevention tool, showing an 80% relative risk reduction in colonization compared to controls. This innovation is particularly relevant amid rising antibiotic resistance, offering a promising alternative to traditional antibiotics and aligning with antimicrobial stewardship principles. The success of this study could enhance Ondine’s market positioning in the multi-billion-dollar ICU infection control market, potentially reducing ICU infection rates, mortality, and healthcare costs.

Ondine Biomedical’s Steriwave Piloted at Royal Papworth Hospital

Ondine Biomedical Inc. has announced a pilot program at the Royal Papworth Hospital NHS Foundation Trust to integrate its Steriwave nasal photodisinfection therapy into cardiac surgical care pathways. This initiative aims to enhance patient safety and surgical outcomes by reducing surgical site infections, particularly in the context of rising antimicrobial resistance. The pilot positions Royal Papworth among a growing list of cardiac centers adopting pre-surgical nasal photodisinfection protocols, with previous implementations showing significant reductions in infections. The Steriwave technology offers a rapid, non-antibiotic solution that does not induce resistance, making it a valuable tool in infection prevention strategies.

Ondine Biomedical Expands Steriwave Adoption and Advances Clinical Trials in H1 2025

Ondine Biomedical Inc. reported significant commercial expansion and clinical progress in the first half of 2025, with a 41% increase in the adoption of its Steriwave® technology across hospitals, including major Canadian and NHS sites. The company is advancing its largest clinical program, a U.S. Phase 3 trial, to support FDA submission, and has completed its first ICU-based Steriwave trial, indicating potential for broader clinical application in critical care. Financially, Ondine saw an 18% increase in revenue to $1.01 million, though operational losses rose due to trial costs. The company secured additional capital, strengthening its financial position, and is focused on expanding its market presence and operational capabilities to support long-term growth.

Ondine Biomedical’s Steriwave Adopted by Mater Hospital to Tackle AMR in Cancer Care

Ondine Biomedical Inc. announced that The Mater Hospital in North Sydney has adopted its Steriwave nasal photodisinfection technology to combat antimicrobial resistance (AMR) in cancer care. This move addresses the heightened risk of drug-resistant infections among cancer patients, particularly those undergoing treatments like chemotherapy and surgery. Steriwave offers a non-invasive, cost-effective solution that reduces infection rates and supports uninterrupted cancer therapies, highlighting its potential to improve patient outcomes and ease healthcare burdens.

Ondine Biomedical to Announce Interim Financial Results

Ondine Biomedical Inc. announced it will release its unaudited interim financial results for the period ending 30 June 2025 on 26 September 2025. A live presentation of the results will be conducted by Dr. Nicolas Loebel and Alan Thomas, which is open to all existing and potential shareholders. This announcement provides an opportunity for stakeholders to gain insights into the company’s financial performance and strategic direction, potentially impacting investor confidence and market positioning.

Ondine Biomedical’s Steriwave Shows Major Economic and Health Benefits at ICPIC 2025

Ondine Biomedical Inc. presented significant findings at the ICPIC 2025 conference, demonstrating the economic and health benefits of its Steriwave nasal photodisinfection technology. The analysis, conducted by the York Health Economics Consortium, showed that using Steriwave could reduce surgical site infections (SSIs) by over 40,000 annually in the UK, resulting in potential cost savings of over £190 million. This innovation not only improves patient outcomes by significantly reducing infection rates compared to existing treatments like Octenisan and mupirocin but also offers substantial economic value by decreasing hospital readmissions and extended stays.

Ondine Biomedical’s Steriwave Technology Proves Effective Against Drug-Resistant Fungus

Ondine Biomedical Inc. has announced that its Steriwave photodisinfection technology is 99.9% effective against the drug-resistant fungus C. auris, which has seen a 67% increase in cases in EU hospitals over the last year. This development is significant as C. auris poses a major threat to healthcare systems due to its resistance to most disinfectants and high mortality rate, with the potential to incur substantial costs in containment and treatment. Ondine’s technology offers a promising solution to manage the rising burden of invasive fungal infections, which have become a growing public health concern worldwide.

Ondine Biomedical Grants 300,000 Share Options to Consultant

Ondine Biomedical Inc. has announced the grant of 300,000 options to a key consultant, allowing them to subscribe for new common shares at an exercise price of 15.50 pence. These options will vest over three years and can be exercised within eight years, contributing to a total of 18,863,334 options outstanding, which represents 3.64% of the company’s current issued share capital.

Ondine Biomedical’s Steriwave Gains Global Attention on CNBC

Ondine Biomedical’s Steriwave nasal photodisinfection technology was recently featured on CNBC’s Worldwide Exchange, where former Mexican President Vicente Fox highlighted its potential in addressing global antibiotic resistance, particularly in developing nations. The feature underscores Ondine’s leadership in non-antibiotic infection-prevention solutions and aligns with their mission to combat multidrug-resistant infections worldwide. This media attention supports the company’s strategic initiative, Light Against AMR, aimed at deploying affordable, light-based infection control technologies in underserved markets.